DBV Technologies: widening nine-month net loss

(CercleFinance.com) - Biopharmaceutical company DBV Technologies has reported a net loss for the first nine months of 2024 of $90.
9 million, compared with $61.5 million at the end of September 2023, mainly due to a 35% increase in operating expenses to $96.4 million.

This was mainly due to higher R&D expenses resulting in particular from accelerated patient recruitment in the VITESSE Phase 3 clinical trial and preparatory activities for the COMFORT studies.

Based on current operations, plans and assumptions, DBV expects its cash balance and cash equivalents of 46.4 million at September 30 to be sufficient to finance its operations until the first quarter of 2025.

Copyright (c) 2024 CercleFinance.com. All rights reserved.